EC competition clears advisory panel
This article was originally published in The Tan Sheet
Executive Summary
FDA's Advisory Committee for Reproductive Health Drugs June 17 votes unanimously in favor of approving Watson Pharmaceuticals' emergency contraceptive ulipristal acetate, marketed in Europe as ellaOne by HRA Pharma. Collins Stewart analyst Louise Chen said in a same-day note the panel's decision bodes well for FDA approval and a likely early 2011 launch for UPA, which Chen expects to compete with Teva's Plan B One-Step (levonorgestrel). Although UPA would be available Rx-only upon approval, Watson CEO Paul Bisaro has stated an interest in switching the next-generation EC to nonprescription status (1"The Tan Sheet" March 15, 2010, In Brief)
You may also be interested in...
Watson plans OTC switch for EC
A next-generation emergency contraceptive could switch to nonprescription status eventually, according to Watson Pharmaceuticals, which licensed ulipristal acetate from HRA Pharma Feb. 1. "Ultimately, I suspect in time we will try to get the product to go OTC, just like the Plan B product," said CEO Paul Bisaro. Bisaro, speaking at the CLSA/Asia USA Investor's Forum in San Francisco March 2, noted UPA demonstrated high effectiveness for five days after unprotected sex. UPA is marketed in Europe as ellaOne by HRA Pharma and is currently in the new drug application stage with FDA
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.